Africa's Cancer Research Company


We use cutting edge immunogenomics, bioinformatics and artificial intelligence to accelerate the development of cancer detection and cure strategies, ultimately with the goal of lowering the economic burden of cancer on the African continent.


Learn More
 

What We Do

We are focused on improving cancer care through greater understanding of human genetic diversity.

About Us

Our Mission

Our mission is to redefine how cancer is diagnosed and treated in Africa, through innovative, sustainable biomedical research and partnerships that aid in the advancement of medicine across the continent. This includes:

  • Optimise existing molecular diagnostic and prognostic tests for African populations and provide these as part of screening service.
  • Identify novel biomarkers for early detection of cancer among African populations and develop novel diagnostic tools based on these markers
  • Engage with local community to promote cancer awareness, stressing the importance of early detection and providing education on the utility of molecular (genomic) techniques in aiding in the diagnosis and prognosis of cancer.
  • Accelerate adoption of personalised medicine among African population.
 

News


March 21, 2022

Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally

Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
February 22, 2022

Yemaachi Launches HPV Molecular Test in Ghana for At-Home Cervical Cancer Risk Assessment

GenomeWeb covers Yemaachi's launch of its Sheba HPV Test, a convenient discreet way for women to screen themselves for HPV and assess their risk for cervical cancer.
January 27, 2022

First study to monitor COVID-19 vaccine-induced immune responses in Africa

Yemaachi Biotech's Heritage Study is the first of its kind to compare immune responses to the same vaccine in both African and European populations, and could provide important insights into how vaccines can be optimally designed for African people
 

Contact details

Do you have any questions about our services?

222 Swaniker Street,
Abelempke, Accra,
Ghana


+233 (0)502 528 528
info@yemaachi.com